Noclaud (Cilostazol)

Cilostazol acts on the peripheral vascular system to relieve ischemic symptoms and improve exercise tolerance.

• Intermittent claudication: increases maximum walking distance and reduces leg pain during exertion.
• Peripheral arterial disease: alleviates symptoms such as cramping and fatigue in the lower limbs.
• Exercise tolerance: enhances overall walking capacity in patients with chronic limb ischemia.

• Cilostazol selectively inhibits phosphodiesterase III, leading to elevated intracellular cyclic AMP in platelets and vascular smooth‑muscle cells. The rise in cAMP suppresses platelet aggregation and promotes vasodilation, thereby improving blood flow to peripheral tissues and reducing ischemic symptoms.

Cilostazol may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Diarrhea: loose stools that may resolve with continued therapy.
• Dizziness: sensation of light‑headedness, especially on standing.
• Palpitations: awareness of heartbeats, usually benign.
• Nausea: upset stomach, may improve over time.
• Abdominal pain: discomfort in the upper abdomen.

Serious or Rare Side Effects

• Thrombocytopenia: marked reduction in platelet count requiring monitoring.
• Severe bleeding: gastrointestinal or intracranial hemorrhage.
• Myocardial ischemia: chest pain or angina in susceptible patients.
• Arrhythmia: abnormal heart rhythms, potentially life‑threatening.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Severe allergic reactions: rash, swelling, or anaphylaxis.

Before initiating cilostazol therapy, clinicians should assess individual risk factors and monitor patients regularly.

• Cardiovascular assessment: evaluate for heart failure or recent myocardial infarction.
• Blood pressure monitoring: watch for hypotension, especially in dehydrated patients.
• Liver function: check hepatic enzymes and adjust if significant impairment exists.
• Bleeding risk: avoid in patients with active bleeding or recent major surgery.
• Concomitant anticoagulants: use caution as combined therapy may increase bleeding.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Cilostazol can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole): increase cilostazol plasma concentrations.
• CYP2C19 inhibitors (e.g., omeprazole): raise exposure and risk of adverse effects.
• Anticoagulants (e.g., warfarin): potentiate bleeding risk.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (e.g., aspirin): additive antithrombotic effect.
• Beta‑blockers: may mask tachycardia caused by cilostazol.
• Diuretics: can enhance hypotensive response.